{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:25:38Z","timestamp":1757611538787,"version":"3.44.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":205,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.100972","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T06:36:17Z","timestamp":1753511777000},"page":"100972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["First-line durvalumab plus platinum\u2013etoposide in Japanese patients with extensive-stage small-cell lung cancer"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4306-7737","authenticated-orcid":false,"given":"Eisuke","family":"Mochizuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Koshimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Watanuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryunosuke","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Takuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Karayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Inui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ctarc.2025.100972_bib0001","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2025.0560","article-title":"Small cell lung cancer: a review","volume":"333","author":"Kim","year":"2025","journal-title":"JAMa"},{"issue":"4","key":"10.1016\/j.ctarc.2025.100972_bib0002","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.resinv.2025.05.013","article-title":"Treatment of small cell lung cancer; advances and future prospects","volume":"63","author":"Niho","year":"2025","journal-title":"Respir. Investig."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100972_bib0003","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100972_bib0004","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41598-017-01571-0","article-title":"Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100972_bib0005","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.29098","article-title":"Small cell lung cancer: where do we go from here?","volume":"121","author":"Byers","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100972_bib0006","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100972_bib0007","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Cancer J. Clin."},{"issue":"23","key":"10.1016\/j.ctarc.2025.100972_bib0008","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.ctarc.2025.100972_bib0009","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ctarc.2025.100972_bib0010","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100972_bib0011","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2217\/fon.12.25","article-title":"Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy","volume":"8","author":"Soo","year":"2012","journal-title":"Future Oncol."},{"issue":"Suppl 13","key":"10.1016\/j.ctarc.2025.100972_bib0012","article-title":"Immunotherapy in the Asiatic population: any differences from Caucasian population?","volume":"10","author":"Peng","year":"2018","journal-title":"J. Thorac. Dis."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100972_bib0013","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1164\/rccm.200611-1696OC","article-title":"Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival","volume":"177","author":"Sumikawa","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100972_bib0014","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.ejrad.2015.01.021","article-title":"Interstitial lung abnormalities in treatment-na\u00efve advanced non-small-cell lung cancer patients are associated with shorter survival","volume":"84","author":"Nishino","year":"2015","journal-title":"Eur. J. Radiol."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100972_bib0015","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.resinv.2019.05.002","article-title":"Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer","volume":"57","author":"Nakanishi","year":"2019","journal-title":"Respir. Investig."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100972_bib0016","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0169-5002(02)00072-7","article-title":"Staging small cell lung cancer: veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer\u2013what limits limited disease?","volume":"37","author":"Micke","year":"2002","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2025.100972_bib0017","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s10147-021-01899-8","article-title":"First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis","volume":"26","author":"Hotta","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2025.100972_bib0018","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.21037\/tlcr-24-128","article-title":"Durvalumab plus platinum-etoposide chemotherapy for extensive-stage small cell lung cancer: a retrospective real-world study","volume":"13","author":"Misawa","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"doi-asserted-by":"crossref","unstructured":"Rittmeyer A., et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Lancet. 2017;389(10066):255\u2013265. doi: 10.1016\/S0140-6736(16)32517-X.","key":"10.1016\/j.ctarc.2025.100972_bib0019","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"10.1016\/j.ctarc.2025.100972_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693279","article-title":"Case report: durvalumab-associated encephalitis in extensive-stage small cell lung carcinoma","volume":"11","author":"Shionoya","year":"2021","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100972_bib0021","doi-asserted-by":"crossref","DOI":"10.1177\/03000605241287015","article-title":"Autoimmune encephalitis following treatment with durvalumab for small-cell lung cancer","volume":"52","author":"Qian","year":"2024","journal-title":"J. Int. Med. Res."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100972_bib0022","first-page":"1175","article-title":"Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease","volume":"33","author":"Yoshida","year":"2013","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100972_bib0023","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/JTO.0b013e3182103d3c","article-title":"The feasibility study of carboplatin plus etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias","volume":"6","author":"Minegishi","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.ctarc.2025.100972_bib0024","article-title":"Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis","volume":"2","author":"Vansteenkiste","year":"2017","journal-title":"ESMo Open."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100972_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221718","article-title":"Idiopathic pulmonary fibrosis in small cell lung cancer as a predictive factor for poor clinical outcome and risk of its exacerbation","volume":"14","author":"Koyama","year":"2019","journal-title":"PLoS. One"},{"issue":"10","key":"10.1016\/j.ctarc.2025.100972_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20463","article-title":"Drug-induced interstitial lung disease after chemoimmunotherapy for extensive-stage small cell lung cancer","volume":"9","author":"Fukuda","year":"2023","journal-title":"Heliyon."},{"issue":"34","key":"10.1016\/j.ctarc.2025.100972_bib0027","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/1759-7714.15471","article-title":"First-line chemoimmunotherapy for patients with small-cell lung cancer and interstitial lung abnormality: CIP risk and prognostic analysis","volume":"15","author":"Li","year":"2024","journal-title":"Thorac. Cancer"},{"issue":"22","key":"10.1016\/j.ctarc.2025.100972_bib0028","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100972_bib0029","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422500108X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246829422500108X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T21:17:21Z","timestamp":1756934241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246829422500108X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":29,"alternative-id":["S246829422500108X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100972","relation":{},"ISSN":["2468-2942"],"issn-type":[{"type":"print","value":"2468-2942"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line durvalumab plus platinum\u2013etoposide in Japanese patients with extensive-stage small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100972"}}